Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19
Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic.
Main Authors: | , , , , , , , , , |
---|---|
Format: | info:ar-repo/semantics/artículo biblioteca |
Language: | eng |
Published: |
Elsevier
2021-12-09T13:43:44Z
|
Subjects: | COVID-19, Coronavirus del Síndrome Respiratorio Agudo Grave 2, Diagnóstico, ELISA, Técnicas Inmunológicas, Severe Acute Respiratory Syndrome Coronavirus 2, Diagnosis, Immunological Techniques, SARS-CoV-2, |
Online Access: | http://hdl.handle.net/20.500.12123/10871 https://www.sciencedirect.com/science/article/pii/S0022175921002271 https://doi.org/10.1016/j.jim.2021.113182 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:localhost:20.500.12123-10871 |
---|---|
record_format |
koha |
institution |
INTA AR |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-inta-ar |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Biblioteca Central del INTA Argentina |
language |
eng |
topic |
COVID-19 Coronavirus del Síndrome Respiratorio Agudo Grave 2 Diagnóstico ELISA Técnicas Inmunológicas Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Immunological Techniques SARS-CoV-2 COVID-19 Coronavirus del Síndrome Respiratorio Agudo Grave 2 Diagnóstico ELISA Técnicas Inmunológicas Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Immunological Techniques SARS-CoV-2 |
spellingShingle |
COVID-19 Coronavirus del Síndrome Respiratorio Agudo Grave 2 Diagnóstico ELISA Técnicas Inmunológicas Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Immunological Techniques SARS-CoV-2 COVID-19 Coronavirus del Síndrome Respiratorio Agudo Grave 2 Diagnóstico ELISA Técnicas Inmunológicas Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Immunological Techniques SARS-CoV-2 Villafañe, Luciana María Gallo Vaulet, Maria Lucia Viere, Florencia M. Klepp, Laura Ines Forrellad, Marina Andrea Bigi, María Mercedes Romano, Maria Isabel Magistrelli, Giovanni Rodríguez Fermepin, Marcelo Bigi, Fabiana Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 |
description |
Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic. |
format |
info:ar-repo/semantics/artículo |
topic_facet |
COVID-19 Coronavirus del Síndrome Respiratorio Agudo Grave 2 Diagnóstico ELISA Técnicas Inmunológicas Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Immunological Techniques SARS-CoV-2 |
author |
Villafañe, Luciana María Gallo Vaulet, Maria Lucia Viere, Florencia M. Klepp, Laura Ines Forrellad, Marina Andrea Bigi, María Mercedes Romano, Maria Isabel Magistrelli, Giovanni Rodríguez Fermepin, Marcelo Bigi, Fabiana |
author_facet |
Villafañe, Luciana María Gallo Vaulet, Maria Lucia Viere, Florencia M. Klepp, Laura Ines Forrellad, Marina Andrea Bigi, María Mercedes Romano, Maria Isabel Magistrelli, Giovanni Rodríguez Fermepin, Marcelo Bigi, Fabiana |
author_sort |
Villafañe, Luciana María |
title |
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 |
title_short |
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 |
title_full |
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 |
title_fullStr |
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 |
title_full_unstemmed |
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 |
title_sort |
development and evaluation of a low cost igg elisa test based in rbd protein for covid-19 |
publisher |
Elsevier |
publishDate |
2021-12-09T13:43:44Z |
url |
http://hdl.handle.net/20.500.12123/10871 https://www.sciencedirect.com/science/article/pii/S0022175921002271 https://doi.org/10.1016/j.jim.2021.113182 |
work_keys_str_mv |
AT villafanelucianamaria developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT gallovauletmarialucia developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT viereflorenciam developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT klepplauraines developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT forrelladmarinaandrea developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT bigimariamercedes developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT romanomariaisabel developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT magistrelligiovanni developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT rodriguezfermepinmarcelo developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 AT bigifabiana developmentandevaluationofalowcostiggelisatestbasedinrbdproteinforcovid19 |
_version_ |
1756008232121270273 |
spelling |
oai:localhost:20.500.12123-108712021-12-09T13:49:11Z Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19 Villafañe, Luciana María Gallo Vaulet, Maria Lucia Viere, Florencia M. Klepp, Laura Ines Forrellad, Marina Andrea Bigi, María Mercedes Romano, Maria Isabel Magistrelli, Giovanni Rodríguez Fermepin, Marcelo Bigi, Fabiana COVID-19 Coronavirus del Síndrome Respiratorio Agudo Grave 2 Diagnóstico ELISA Técnicas Inmunológicas Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Immunological Techniques SARS-CoV-2 Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic. Instituto de Biotecnología Fil: Villafañe, Luciana Maria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular (IABIMO); Argentina Fil: Villafañe, Luciana Maria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gallo Vaulet, Maria Lucia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina Fil: Gallo Vaulet, Maria Lucia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Viere, Florencia M. Universidad de Buenos Aires. Facultad de Medicina; Argentina Fil: Klepp, Laura Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular (IABIMO); Argentina Fil: Klepp, Laura Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Forrellad, Marina Andrea. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular (IABIMO); Argentina Fil: Forrellad, Marina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Bigi, María Mercedes. Universidad de Buenos Aires. Instituto De Investigaciones Biomédicas; Argentina Fil: Romano, Maria Isabel. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular (IABIMO); Argentina Fil: Romano, Maria Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Magistrelli, Giovanni. Light Chain Bioscience – Novimmune SA; Suiza Fil: Rodríguez Fermepin, Marcelo. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina Fil: Rodríguez Fermepin, Marcelo. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina Fil: Bigi, Fabiana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular (IABIMO); Argentina Fil: Bigi, Fabiana. Consejo Nacional de investigaciones Científicas y Tecnológicas; Argentina info:eu-repo/date/embargoEnd/2022-12-09 2021-12-09T13:43:44Z 2021-12-09T13:43:44Z 2022-01 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion http://hdl.handle.net/20.500.12123/10871 https://www.sciencedirect.com/science/article/pii/S0022175921002271 0022-1759 https://doi.org/10.1016/j.jim.2021.113182 eng info:eu-repograntAgreement/INTA/2019-PD-E5-I102-001/2019-PD-E5-I102-001/AR./Desarrollo de vacunas y tecnologías para mejorar las estrategias profilácticas y terapéuticas de las enfermedades que afectan la producción animal y la salud pública info:eu-repo/semantics/embargoedAccess application/pdf Elsevier Journal of Immunological Methods 500 : 113182 (January 2022) |